Regorafenib with a fluoropyrimidine for metastatic colorectal cancer after progression on multiple 5-FU-containing combination therapies and regorafenib monotherapy

References

• Siegel RL, Miller KD, Jemal A. Cancer statistics, 2015. CA Cancer J Clin 2015; 65(1):5–29; PMID:25559415; http://dx.doi.org/10.3322/caac.21254
   PubMed Web of Science ®Google Scholar
• Ferlay J, Soerjomataram I, Ervik M, Dikshit R, Eser S, Mathers C, Rebelo M, Parkin DM, Forman D, Bray, F. GLOBOCAN 2012 v1.0, Cancer Incidence and Mortality Worldwide: IARC CancerBase No. 11 [Internet]. 2013 ( Available from: http://globocan.iarc.fr, accessed on 9/12/2015).
   Google Scholar
• Van Cutsem E, Nordlinger B, Adam R, Kohne CH, Pozzo C, Poston G, Ychou M, Rougier P, European Colorectal Metastases Treatment Group. Towards a pan-European consensus on the treatment of patients with colorectal liver metastases. Euro J Cancer 2006; 42(14):2212–21; PMID:16904315; http://dx.doi.org/10.1016/j.ejca.2006.04.012
   PubMed Web of Science ®Google Scholar
• Benson AB, Venook A, Bekaii-Saab T, Chan E, Chen YJ, Cooper HS, Engstrom PF, Enzinger PC, Fenton MJ, Fuchs CS, et al. Rectal Cancer Version 2.2015. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines ®), 2015
   Google Scholar
• Rothenberg ML, Oza AM, Bigelow RH, Berlin JD, Marshall JL, Ramanathan RK, Hart LL, Gupta S, Garay CA, Burger BG, et al. Superiority of oxaliplatin and fluorouracil-leucovorin compared with either therapy alone in patients with progressive colorectal cancer after irinotecan and fluorouracil-leucovorin: interim results of a phase III trial. J Clin Oncol 2003; 21(11):2059–69; PMID:12775730; http://dx.doi.org/10.1200/JCO.2003.11.126
   PubMed Web of Science ®Google Scholar
• Gubanski M, Naucler G, Almerud A, Lidestahl A, Lind PA. Capecitabine as third line therapy in patients with advanced colorectal cancer. Acta Oncol 2005; 44(3):236–9; PMID:16076695; http://dx.doi.org/10.1080/02841860510029662
   PubMed Web of Science ®Google Scholar
• Mayer RJ, Van Cutsem E, Falcone A, Yoshino T, Garcia-Carbonero R, Mizunuma N, Yamazaki K, Shimada Y, Tabernero J, Komatsu Y, et al. Randomized trial of TAS-102 for refractory metastatic colorectal cancer. N Engl J Med 2015; 372(20):1909–19; PMID:25970050; http://dx.doi.org/10.1056/NEJMoa14-14325
   PubMed Web of Science ®Google Scholar
• Wilhelm SM, Dumas J, Adnane L, Lynch M, Carter CA, Schutz G, Thierauch KH, Zopf D. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 2011; 129(1):245–55; PMID:21170960; http://dx.doi.org/10.1002/ijc.25864
   PubMed Web of Science ®Google Scholar
• Strumberg D, Scheulen ME, Schultheis B, Richly H, Frost A, Buchert M, Christensen O, Jeffers M, Heinig R, Boix O, et al. Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study. Br J Cancer 2012; 106(11):1722–7; PMID:22568966; http://dx.doi.org/10.1038/bjc.2012.153
   PubMed Web of Science ®Google Scholar
• Mross K, Frost A, Steinbild S, Hedbom S, Buchert M, Fasol U, Unger C, Krätzschmar J, Heinig R, Boix O, et al. A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors. Clin Cancer Res 2012; 18(9):2658–67; PMID:22421192; http://dx.doi.org/10.1158/1078-0432.CCR-11-1900
   PubMed Web of Science ®Google Scholar
• Grothey A, Van Cutsem E, Sobrero A, Siena S, Falcone A, Ychou M, Humblet Y, Bouché O, Mineur L, Barone C, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 2013; 381(9863):303–12; PMID:23177514; http://dx.doi.org/10.1016/S0140-6736(12)61900-X
   PubMed Web of Science ®Google Scholar
• Research Center for Drug Evaluation and Research. Approved Drugs – Regorafenib [Internet]. U.S. Food and Drug Administration Center for Drug Evaluation and Research, 2015. [updated 09/27/2012 ; cited 12/9/2015].( Available from:http://www.fda.gov/drugs/informationondrugs/approveddrugs/ucm321378.htm)
   Google Scholar
• Carter NJ. Regorafenib: a review of its use in previously treated patients with progressive metastatic colorectal cancer. Drugs Aging 2014; 31(1):67–78; PMID:24276917; http://dx.doi.org/10.1007/s40266-013-0140-6
   PubMed Web of Science ®Google Scholar
• Van Cutsem EPM, Siena S, Humblet Y, Hendlisz A, Neyns B, Canon JL, Van Laethem JL, Maurel J, Richardson G, Wolf M, et al. Open-label phase III trial of panitumumab plus best supportive care compared with best supportive care alone in patients with chemotherapy-refractory metastatic colorectal cancer. J Clin Oncol 2007; 25:1658–64.; PMID:17470858; http://dx.doi.org/10.1200/JCO.2006.08.1620
   PubMed Web of Science ®Google Scholar
• Jonker DJ, O'Callaghan CJ, Karapetis CS, Zalcberg JR, Tu D, Au HJ, Berry SR, Krahn M, Price T, Simes RJ, et al. Cetuximab for the treatment of colorectal cancer. N Engl J Med 2007; 357(20):2040–8; PMID:18003960; http://dx.doi.org/10.1056/NEJMoa071834
   PubMed Web of Science ®Google Scholar
• Foubert F, Matysiak-Budnik T, Touchefeu Y. Options for metastatic colorectal cancer beyond the second line of treatment. Dig Liver Dis 2014; 46(2):105–12; PMID:23954144; http://dx.doi.org/10.1016/j.dld.2013.07.002
   PubMedGoogle Scholar
• Lu CY, Yeh YS, Huang CW, Ma CJ, Yu FJ, Wang JY. FOLFIRI and regorafenib combination therapy with dose escalation of irinotecan as fourth-line treatment for patients with metastatic colon cancer according to UGT1A1 genotyping. Onco Targets Ther 2014; 7:2143–6; PMID:25473295; http://dx.doi.org/10.2147
   PubMed Web of Science ®Google Scholar
• Schultheis B, Folprecht G, Kuhlmann J, Ehrenberg R, Hacker UT, Köhne CH, Kornacker M, Boix O, Lettieri J, Krauss J, et al. Regorafenib in combination with FOLFOX or FOLFIRI as first- or second-line treatment of colorectal cancer: results of a multicenter, phase Ib study. Ann Oncol 2013; 24(6):1560–7; PMID:23493136; http://dx.doi.org/10.1093/annonc/mdt056
   PubMed Web of Science ®Google Scholar
• Argiles G, Saunders MP, Rivera F, Sobrero A, Benson A 3rd, Guillen Ponce C, Cascinu S, Van Cutsem E, Macpherson IR, Strumberg D, et al. Regorafenib plus modified FOLFOX6 as first-line treatment of metastatic colorectal cancer: A phase II trial. Eur J Cancer 2015; 51(8):942–9; PMID:25818084; http://dx.doi.org/10.1016/j.ejca.2015.02.013
   PubMed Web of Science ®Google Scholar
• Tournigand C, André T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J Clin Oncol 2004; 22(2):229–37; PMID:14657227; http://dx.doi.org/10.1200/JCO.2004.05.113
   PubMed Web of Science ®Google Scholar
• Carr BI, Cavallini A, Lippolis C, D'Alessandro R, Messa C, Refolo MG, Quinaux E, Couteau C, Buyse M, Ganem G, et al. Fluoro-Sorafenib (Regorafenib) effects on hepatoma cells: growth inhibition, quiescence, and recovery. J Cell Physiol 2013; 228(2):292–7; PMID:22777740; http://dx.doi.org/10.1002/jcp.24148
   PubMed Web of Science ®Google Scholar
• Chen D, Wei L, Yu J, Zhang L. Regorafenib inhibits colorectal tumor growth through PUMA-mediated apoptosis. Clin Cancer Res 2014; 20(13):3472–84; PMID:24763611; http://dx.doi.org/10.1158/1078-0432.CCR-13-2944
   PubMed Web of Science ®Google Scholar
• Plastaras JP, Kim SH, Liu YY, Dicker DT, Dorsey JF, McDonough J, Cerniglia G, Rajendran RR, Gupta A, Rustgi AK, et al. Cell cycle dependent and schedule-dependent antitumor effects of sorafenib combined with radiation. Cancer Res 2007; 67(19)9443–9454; PMID:17909054; http://dx.doi.org/10.1158/0008-5472.CAN-07-1473
   PubMed Web of Science ®Google Scholar